INFORECERCA: Butlletí Informatiu del Servei de Recerca de l'IMIM
Número: 305
17/05/2013
Comentaris i suggeriments
Banner-noves-convocatories-02
Cercador de convocatòries
Projectes
Termini exhaurit
RecerCaixa 2017
La convocatòria d’ajuts a la recerca RecerCaixa finançarà projectes de recerca desenvolupats per investigadors i investigadores de les universitats i centres de recerca de Catalunya.
La convocatòria persegueix principalment dos objectius: impulsar la recerca científica d’excel·lència al nostre país i apropar la ciència a la societat per fer-la partícip dels avenços científics i dels beneficis humans i socials de la recerca.
 
Termini exhaurit
DEPARTMENT OF DEFENSE
The Resource Development Award has been established to support product-driven research aimed at developing well-annotated tools for use by the ovarian cancer research community to facilitate research in this disease. Specifically, this includes either developing a human-based resource or increasing the utility of an existing human-based resource.
 
Termini exhaurit
DEPARTMENT OF DEFENSE
The OCRP Translational Leverage Award mechanism supports the leveraging of existing human-based ovarian cancer resources in translational research to address high-impact research ideas or unmet needs in ovarian cancer, particularly correlative or adjunct analyses associated with clinical trials. Clinical trials are not supported by this award mechanism
 
Premis
Termini exhaurit
FUNDACION PRYCONSA
Proporcionar el reconeixement formal a les contribucions d'excel·lència de genetistes professionals en la recerca en genètica i les seves aplicacions en qualsevol àrea d’interès social.
 
Termini exhaurit
SOCIETAT CATALANA DE CIRURGIA
Premiar la tasca d'un cirurgià de dins i de fora de l'Estat Espanyol, en reconeixement dels mèrits obtinguts al llarg de la seva vida professional.
 
Recursos Humans
Termini exhaurit
DEPARTMENT OF DEFENSE
The OCRP Pilot Award supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward. The proposed research should include a testable hypothesis based on strong scientific rationale and serve a catalyst to expand or modify current thinking about and/or approaches in ovarian cancer research. Preliminary data are not required, but are allowed. The strength of the application should be based on sound scientific rationale and logical reasoning. Clinical trials will not be supported by this award mechanism.
 
Termini exhaurit
DEPARTMENT OF DEFENSE
The OCRP Teal Innovator Award supports a visionary individual from any field principally outside of, but not exclusive of, ovarian cancer to focus his/her creativity, innovation, and leadership on ovarian cancer research. The Teal Innovator Award will provide the Principal Investigator (PI) with the funding and freedom to pursue his/her most novel, visionary, high-risk ideas that could significantly impact the field of ovarian cancer research or patient care.
 
 
 
Informació últil
 
 
 
 
Banner-convocatories-tancament-02
Projectes
Termini exhaurit
RecerCaixa 2017
La convocatòria d’ajuts a la recerca RecerCaixa finançarà projectes de recerca desenvolupats per investigadors i investigadores de les universitats i centres de recerca de Catalunya.
La convocatòria persegueix principalment dos objectius: impulsar la recerca científica d’excel·lència al nostre país i apropar la ciència a la societat per fer-la partícip dels avenços científics i dels beneficis humans i socials de la recerca.
 
Termini exhaurit
ROI - RADIATION ONCOLOGY INSTITUTE
The aim of this request is to examine the comparative value of radiotherapy. The ROI, ASTRO, NCI and IOM call for generation of evidence to demonstrate the value of technologies and interventions in radiation oncology. Value encompasses aspects of both comparative and cost effectiveness but can be more broadly defined to include innovative approaches to evaluating the benefits and harms of radiation oncology interventions. The ROI supports studies that examine the comparative value of radiotherapy because such studies have the potential to generate the evidence needed to improve cancer outcomes while slowing the growth of health care spending.
 
Termini exhaurit
DEPARTMENT OF DEFENSE
The Prostate Cancer Research Program seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.
 
Termini exhaurit
DEPARTMENT OF DEFENSE
The Resource Development Award has been established to support product-driven research aimed at developing well-annotated tools for use by the ovarian cancer research community to facilitate research in this disease. Specifically, this includes either developing a human-based resource or increasing the utility of an existing human-based resource.
 
Termini exhaurit
DEPARTMENT OF DEFENSE
The OCRP Translational Leverage Award mechanism supports the leveraging of existing human-based ovarian cancer resources in translational research to address high-impact research ideas or unmet needs in ovarian cancer, particularly correlative or adjunct analyses associated with clinical trials. Clinical trials are not supported by this award mechanism
 
Termini exhaurit
COIB - COL·LEGI OFICIAL D'INFERMERES I INFERMERS DE BARCELONA
L’objectiu principal és potenciar l’increment qualitatiu i quantitatiu de la recerca infermera, donar ajuda econòmica per a la realització d’investigacions infermeres i potenciar aquells investigadors principals que debuten en la recerca.
 
Termini exhaurit
L'ORÉAL CORPORATE FOUNDATION
Estan dirigides a joves científiques dedicades a Ciències de la Vida que desenvolupin al llarg de l'any 2014 un projecte d'investigació en un laboratori.
 
Termini exhaurit
MUSCULAR DYSTROPHY ASSOCIATION
MDA supports research aimed at developing treatments for the muscular dystrophies and related diseases of the neuromuscular system. These are the muscular dystrophies (among which are Duchenne and Becker); motor neuron diseases (including ALS and SMA); the peripheral nerve disorders (CMT and Friedreich's ataxia); inflammatory myopathies; disorders of the neuromuscular junction; metabolic diseases of muscle as well as other myopathies.
 
Termini exhaurit
JDRF - JUVENILE DIABETES RESEARCH FOUNDATION
JDRF is the world’s leading non-profit organization with the mission to cure type 1 diabetes (T1D). The purpose of this call is to invite proposals to support and advance the discovery, development, and/or validation of biomarkers of pancreatic beta cell stress and dysfunction. Studies based on use or validation with human beta cells/islets and clinical samples or tissues will be of special interest.
 
Borses de viatge
Termini exhaurit
FUNDACIÓ PRIVADA DANIEL BRAVO ANDREU
Promoure el desenvolupament de la recerca cardiològica a Catalunya. Per el que convoca dues beques per a estades d’ entre 3 i 6 mesos per a la col·laboració en projectes i grups d'investigació en ciència cardiovascular a centres estrangers (Europa, Estats Units o Canadà) de prestigi.
 
Premis
Termini exhaurit
EPPENDORF AG
The Prize is awarded annually to one young scientist for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by him/her during the past three years.
 
Termini exhaurit
INSTITUTO DE NEUROCIENCIAS DE ALICANTE
Recompensar la labor científica d'un investigador dedicat a l'estudi de temes de neurobiologia del desenvolupament des de qualsevol perspectiva, que hagi fet aportacions científiques significatives en aquest camp i es trobi en un període de la seva carrera científica, ascendent i d'alta productivitat.
 
Recursos Humans
Termini exhaurit
DEPARTMENT OF DEFENSE
The OCRP Pilot Award supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward. The proposed research should include a testable hypothesis based on strong scientific rationale and serve a catalyst to expand or modify current thinking about and/or approaches in ovarian cancer research. Preliminary data are not required, but are allowed. The strength of the application should be based on sound scientific rationale and logical reasoning. Clinical trials will not be supported by this award mechanism.
 
Termini exhaurit
DEPARTMENT OF DEFENSE
The OCRP Teal Innovator Award supports a visionary individual from any field principally outside of, but not exclusive of, ovarian cancer to focus his/her creativity, innovation, and leadership on ovarian cancer research. The Teal Innovator Award will provide the Principal Investigator (PI) with the funding and freedom to pursue his/her most novel, visionary, high-risk ideas that could significantly impact the field of ovarian cancer research or patient care.
 
 
 
 
Articles
 
Fonseca F, Martín-Santos R, Roig J, Torrens M. Etude pharmacogenetique de la reponse au traitement ala methadone. Pharmacogenetics of methadone treatment response. Le Courrier des Addictions 2013; 15(1): 10-15.
 
 
 
Curto-Barredo L*, Silvestre-Salvador JF, Giménez-Arnau AM. Actualización en el tratamiento de la urticaria crónica. Actas Dermosifiliograf 2014; 105(5): 469-482.
 
Prieto-Alhambra D, Nogués X, Javaid MK, Wyman A, Arden NK, Azagra R, Cooper C, Adachi JD, Boonen S, Chapurlat RD, Compston JE, Gehlbach S, Greenspan SL, Hooven FH, Netelenbos JC, Pfeilschifter J, Rossini M, Sambrook PN, Silverman S, Siris ES, Watts NB, Díez-Pérez A*. An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Ann Rheum Dis 2013; 72(6): 911-917.
 
Albanell J, Ciruelos EM, Lluch A*, Muñoz M, Anton-Rodríguez C. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev 2014; 40(1): 41-47.
 
Bazan V*, Grau N, Vallès E, Félez MA, Sanjuás C, Cainzos-Achirica M, Benito B, Jauregui-Abularach M, Gea J, Bruguera J, Martí Almor J. Obstructive Sleep Apnea in Patients with Typical Atrial Flutter: Prevalence and Impact on Arrhythmia Control Outcome. Chest 2013; 143(5): 1277-1283.
 
Purroy F*, Jiménez-Caballero PE, Gorospe A, Torres MJ, Álvarez-Sabín J, Santamarina E, Martínez-Sánchez P, Cánovas D, Freijo MJ, Egido JA, Ramírez-Moreno JM, Alonso-Arias A, Rodríguez Campello A, Casado A, Delgado Mederos R, Martí Fàbregas J, Fuentes B, Silva Y, Quesada H, Cardona P, Morales A, Pérez de la Ossa N, Garcia-Pastor A, Arenillas JF, Segura T, Jiménez C, Masjuan J, on behalf of the Stroke Project of the Spanish Cerebrovascular Diseases Study Group. Recurrent transient ischaemic attack and early risk of stroke: data from the PROMAPA study. J Neurol Neurosurg Psychiatry 2013; 84(6): 596-603.
 
Romero-Gómez M*, Planas R, Ampuero J, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Turnes J. Meta-analysis: pegylated interferon ?-2a achieves higher early virological responses than ?-2b in chronic hepatitis C. Aliment Pharm Therap 2013; 37(11): 1065-1073.
 
Gasch O*, Camoez M, Domínguez MA, Padilla B, Pintado V, Almirante B, Lepe JA, Lagarde M, Ruiz de Gopegui E, Martínez J.A, Montejo M, Torre Cisneros J, Arnáiz A, Goenaga MA, Benito N, Rodríguez-Baño J, Pujol M, on behalf of the REIPI/GEIH Study Groups (...,Horcajada JP, Montero MM, Salvadó M,...). Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2013; 68(6): 1423-1430.
 
Nadal R, Ortega FG, Salido M, Lorente JA, Rodríguez M, Delgado Rodríguez M, Macià M, Fernández A, Corominas JM, García-Puche JL, Rovira-Sanchez P, Solé F, Serrano MJ*. CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy. Int J Cancer 2013; 133(10): 2398-2407.
 
Merseburger AS*, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM, on behalf of the European Treatment Practices Group. Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer. Oncologist 2013; 18(5): 558-567.
 
Arrebola JP*, Pumarega JA, Gasull M, Fariñas-Fernández M, Martín-Olmedo P, Molina-Molina JM, Fernández-Rodríguez M, Porta M, Olea N. Adipose tissue concentrations of persistent organic pollutants and prevalence of type 2 diabetes in adults from Southern Spain. Environ Res 2013; 122: 31-37.
 
Martin-Subero M*, Berk L, Dodd S, Kulkami J, De Castella A, Fitzgerald PB, Berk M. To a broader concept of remission: Rating the health-related quality of life in bipolar disorder. J Affect Disorders 2013; 150(2): 673-676.
 
Hernández-Boluda JC*, Pereira A, Cervantes F, Gómez M, Arellano-Rodrigo E, Álvarez-Larran A, Ferrer-Marin F, Kerguelen A, Márquez JA, Antelo ML, Besses C. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Ann Hematol 2013; 92(6): 771-775.
 
McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, De la Coba C, Montoro M, Bory F, Pérez-Aisa A, Forné M, Gisbert JP*, On behalf of the participant centres. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63(2): 244-249.
 
Morini L, Marchei E, Tarani L, Trivelli M, Rapisardi G, Elicio MR, Ramis J, García-Algar O, Memo L, Pacifici R, Groppi A, Danesino P, Pichini S. Testing Ethylglucuronide in Maternal Hair and Nails for the Assessment of Fetal Exposure to Alcohol: Comparison With Meconium Testing. Ther Drug Monit 2013; 35(3): 402-407.
 
 
Leal-Noval SR, Muñoz M, Asuero M, Contreras E, García-Erce JA, Llau JV, Moral V, Páramo JA, Quintana M, Basora M, Bautista-Paloma FJ, Bisbe E, Bóveda JL, Castillo-Muñoz A, Colomina MJ, Fernández C, Fernández-Mondéjar E, Ferrándiz C, García-de-Lorenzo A, Gomar C, Gómez-Luque A, Izuel M, Jiménez-Yuste V, López-Briz E, López-Fernández ML, Martín-Conde JA, Montoro-Ronsano B, Paniagua C, Romero-Garrido JA, Ruiz JC, Salinas-Argente R, Sánchez C, Torrabadella P, Arellano V, Candela A, Fernández JA, Fernández-Hinojosa E, Puppo A. 2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Actualización del Documento Sevilla. Medicina Intensiva 2013; 37(4): 259-283.
 
Salvans S, Gil MJ*, Pera M, Lorente L, Cots F, Pascual M, Alonso S, ____________, Grande L. Impacto de un programa de rehabilitación multimodal en cirugía electiva colorrectal sobre los costes hospitalarios. Cir Esp 2013; 91(10): 638-644.
 
Pera MR*, Grande L, Maurel J. Management of gastroesophageal cancer: A perspective from Catalonia. Oncologie 2013; 15: 181-188.
 
 
Institut Hospital del Mar d'Investigacions Mèdiques
Tel: 93 316 04 00
Doctor Aiguader, 88
08003 Barcelona
Seguiu-nos a:
Twitter
Youtube
En compliment de la Llei 34/2002, de Serveis de la Societat de la Informació i de Comerç Electrònic, aquest correu li hem enviat a partir de les dades de contacte que vostè ens ha facilitat. Si vostè no desitja rebre més comunicats, pot donar-se de baixa dirigint-se per escrit al Servei de Recursos Humans-IMIM (RRHHconfidencialitat@imim.es) tot indicant la paraula “baixa base de dades” a l’assumpte.
Li recordem que podrà exercir els drets d’accés, rectificació, cancel·lació i oposició dirigint-se per escrit al Servei de Recursos Humans-IMIM (RRHHconfidencialitat@imim.es).